SIR-Spheres® Y-90 resin microspheres are now FDA-approved for unresectable HCC, marking a unique approval for both HCC and mCRC in the U.S. The DOORwaY90 study showed a 98.5% overall response rate and ...
Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, ...
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin ...
Moreover, those patients treated with SIR-Spheres Y-90 resin microspheres who reported treatment-related side effects experienced a median of only 5 such events over the course of the SARAH study, ...
Sirtex Medical Inc. announced its dose sales for SIR-Spheres Y-90 resin microspheres have increased by 21.2% in the U.S. for the second quarter of 2015 compared to the second quarter of 2014, ...
The results, which could impact the treatment of tens of thousands of liver cancer patients annually, were announced by the principal investigator of the SARAH study, Professor Valérie Vilgrain MD, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback